



FOR IMMEDIATE RELEASE

Guardion Health Sciences, Inc.
15150 Avenue of Science, Ste. 200
San Diego, CA 92128
Ph 858.605.9055; Fax 858.630.5543
www.guardionhealth.com

Guardion Health Sciences Files Form S-1 Registration Statement under the Securities Act of 1933

San Diego, California – February 11, 2016 – Guardion Health Sciences, Inc. (“GHS”) today announced that it has filed a Registration Statement on Form S-1 (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”). The Registration Statement has not yet become effective, and is under review and subject to comments by the SEC.

GHS is a specialty health sciences company that is a leader in providing verifiable, validated and proprietary condition-specific solutions in the areas of ocular health and overall physical wellness. GHS has assembled an elite, globally recognized team of scientists, together with practicing medical professionals, to deliver its message and products to the marketplace.

Commented Michael Favish, Chief Executive Officer and Founder of GHS, “This is a first and important step taken by GHS to become a listed, fully reporting public company. As a public company, we will be better positioned to develop GHS into a market leader in the field of ocular health, as well as to unlock value for our shareholders, access the capital markets and take advantage of potential acquisition and expansion opportunities.”

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of any securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product that addresses a depleted macular protective pigment, which is a known risk factor for causing age-related macular degeneration (“AMD”), as well as computer vision syndrome (“CVS”). Guardion Health Sciences, Inc. has also developed a proprietary medical device that accurately measures the macular pigment density.

Guardion Health Sciences, Inc. currently develops and distributes a line of medical foods that restores the macular protective pigment to address AMD and CVS under the brand name Lumega-Z®. Guardion Health Sciences, Inc. is using its own proprietary patent-pending technology embodied in a medical device called the MapcatSF™ that measures the macular pigment. The MapcatSF™ is a patent-pending, non-mydratic, non-invasive device that accurately measures the macular protective pigment density, thereby creating an evidence-based protocol that is shared with the patient

Company Contact:

Vincent J. Roth, Esq.

General Counsel

Telephone: 858.605.9055 Ext. 208

E-mail: vroth@guardionhealth.com

###